OXBDF Quote, Financials, Valuation and Earnings

Autolus Therapeutics Plc has a net margin of -- compared to Oxford Biomedica Plc's net margin of -373.3%. Oxford Biomedica Plc's return on equity of -120.93% beat Autolus Therapeutics Plc's return on equity of -59.51%.

Oxford Biomedica Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 484.19%. Given that Autolus Therapeutics Plc has higher upside potential than Oxford Biomedica Plc, analysts believe Autolus Therapeutics Plc is more attractive than Oxford Biomedica Plc.

Oxford Biomedica Plc has a beta of 1.121, which suggesting that the stock is 12.121% more volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.

Oxford Biomedica Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oxford Biomedica Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.

Oxford Biomedica Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Oxford Biomedica Plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Oxford Biomedica Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oxford Biomedica Plc is 4.46x versus 8.46x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals Plc has a net margin of -- compared to Oxford Biomedica Plc's net margin of --. Oxford Biomedica Plc's return on equity of -120.93% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

Oxford Biomedica Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 4786.03%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Oxford Biomedica Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Oxford Biomedica Plc.

Oxford Biomedica Plc has a beta of 1.121, which suggesting that the stock is 12.121% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.

Oxford Biomedica Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oxford Biomedica Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Oxford Biomedica Plc quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Oxford Biomedica Plc's net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Oxford Biomedica Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oxford Biomedica Plc is 4.46x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

NuCana Plc has a net margin of -- compared to Oxford Biomedica Plc's net margin of --. Oxford Biomedica Plc's return on equity of -120.93% beat NuCana Plc's return on equity of -286.82%.

Oxford Biomedica Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 584169.66%. Given that NuCana Plc has higher upside potential than Oxford Biomedica Plc, analysts believe NuCana Plc is more attractive than Oxford Biomedica Plc.

Oxford Biomedica Plc has a beta of 1.121, which suggesting that the stock is 12.121% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.

Oxford Biomedica Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oxford Biomedica Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.

Oxford Biomedica Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Oxford Biomedica Plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Oxford Biomedica Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oxford Biomedica Plc is 4.46x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.

Tiziana Life Sciences Ltd. has a net margin of -- compared to Oxford Biomedica Plc's net margin of --. Oxford Biomedica Plc's return on equity of -120.93% beat Tiziana Life Sciences Ltd.'s return on equity of --.

Oxford Biomedica Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 425.54%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Oxford Biomedica Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Oxford Biomedica Plc.

Oxford Biomedica Plc has a beta of 1.121, which suggesting that the stock is 12.121% more volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.

Oxford Biomedica Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oxford Biomedica Plc pays -- of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend.

Oxford Biomedica Plc quarterly revenues are --, which are smaller than Tiziana Life Sciences Ltd. quarterly revenues of --. Oxford Biomedica Plc's net income of -- is lower than Tiziana Life Sciences Ltd.'s net income of --. Notably, Oxford Biomedica Plc's price-to-earnings ratio is -- while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oxford Biomedica Plc is 4.46x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.